Studies have demonstrated that nuclear EGFR (nEGFR) acts as a transcription factor regulator involved in tumorigenesis [6, 7], is associated with poorer outcomes in many cancers [8–10], and is implicated in resistance to radiation and anti-EGFR therapies, including cetuximab [11, 12]. This evidence concerns the gene EGFR and cancer.